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Cytoreductive treatment before allogeneic hematopoietic stem cell transplantation (allo-SCT) with the
objective of reducing the incidence of disease relapse post-transplant in patients with myelodysplastic
syndrome (MDS) is a matter of debate. The achievement of complete remission (CR) before allo-SCT improves
post-transplantation outcome, although it is not clear whether this reﬂects the selection of patients with
more responsive disease or is related to a reduction in disease burden. Higher CR rates in patients with MDS
are obtained with induction chemotherapy (ICT) than with hypomethylating agents (HMAs), although HMAs
may be active in patients with complex karyotypes in whom ICT almost invariably fails. Furthermore, HMAs
have a good toxicity proﬁle compared with ICT and may therefore be considered especially in older patients
and in patients with comorbidities. However, all interventions aimed at reducing disease burden before allo-
SCT expose patients to the risk of complications, which may prevent them from undergoing transplantation.
Therefore, up-front allo-SCT is an option, particularly for patients with life-threatening cytopenias. In this
review we discuss the main pretransplant therapeutic approaches and propose a decision-model based on
clinical considerations. However, only prospective randomized trials can address the issue deﬁnitively.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The myelodysplastic syndromes (MDS) are clonal disor-
ders associated with ineffective hematopoiesis, marrow
dysplasia, and blood cytopenias, with a high potential of
progression to acute myeloid leukemia (AML). Survival of
patients left untreated ranges from a few months to several
years, depending on the depth of cytopenias, the percentage
of myeloblasts in the marrow (and blood), cytogenetic ab-
normalities, and, as shown by research, certain genetic mu-
tations [1e6]. Treatment of MDS remains unsatisfactory.
Variable success in the correction of blood cytopenias,
reduction of the proportion of marrow myeloblasts, and
normalization of cytogenetics has been achieved with a
variety of treatment strategies, including the use of immu-
nosuppressive drugs, differentiating agents, classic chemo-
therapy, and hypomethylating agents (HMAs) [7e10].edgments on page 1889.
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14.06.023However, in general, responses have not been complete and
have been of limited duration; prolongation of survival, if
achieved, on average has been in the range of months.
Currently, allogeneic hematopoietic stem cell trans-
plantation (allo-SCT) remains the only approach with cura-
tive potential for patients with higher risk/advanced MDS
[11e13]. Yet, despite the beneﬁcial effects of allo-SCT, post-
transplant relapse is a major cause of failure [8,14].
Whether “debulking” treatment should be given in
preparation for transplantation and the type of such treat-
ment is controversial. AML induction-type chemotherapy
(ICT) has been recommended for younger patients who
present with MDS and more than 5% marrow myeloblasts
[11,13]. However, this approach is associated with consider-
able toxicity that could prohibit the patient from proceeding
to transplantation and might interfere with post-transplant
outcome.
HMAs, especially 5-azacitidine (AZA), have emerged as
therapeutic options that may signiﬁcantly prolong overall
survival (OS) in nontransplanted MDS patients. HMAs are
considered the current standard of care for patients with
intermediate-2 and high-risk MDS (as determined byTransplantation.
Table 1
Pretransplant Strategies
ICT  Higher rate of CR than after HMAs; better outcomes
after transplant, especially in patients undergoing
NMA/RIC
 Favorable cost-effectiveness ratio
 High toxicity (inappropriate for older patients and those with
comorbidities)
 Patient hospitalization required (not an outpatient procedure)
 Ineffective for poor-risk cytogenetics; no beneﬁt with low
marrow blast percentage
 High patient drop-out rate due to complications, not reaching
transplantation
HMAs  Low toxicity proﬁle (appropriate for older patients
and those with comorbidities)
 Administration to outpatients
 More effective than ICT in patients with unfavorable
cytogenetics
 Cost of treatment
 Lower CR rate
 Long treatment duration: multiple cycles of treatment are needed
before response can be assessed
 Responses to treatment are of short duration in patients with
unfavorable cytogenetics
 High patient drop-out rate (not reaching transplantation) due to
complications from pretransplant treatment or rapid progression
to AML
Up-front allo-SCT  No debulking-treatment-related toxicity
 Allo-SCT can be performed as soon as a suitable
donor is identiﬁed
 Risk of transformation to AML before allo-SCT
 Post-transplant interventions may be necessary, especially in
patients undergoing NMA/RIC
 Increased risk of post-transplant relapse in patients transplanted
with progressive disease
CR indicates complete remission; NMA, nonmyeloablative conditioning.
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although their use is not curative [9,15]. The aim of this
report is to discuss the issue of whether patients should
receive pretransplant “debulking” therapy to reduce the risk
of post-transplant relapse and, if so, what the optimal mo-
dality should be (Table 1).
INDUCTION-TYPE CHEMOTHERAPY
In Favor of ICT
Pretransplant therapy in patients with MDS can buy time
to transplantation, as a bridging strategy. By inducing
cytoreduction or, in a limited number of patients, even
complete remissions, this approach may reduce the risk of
post-transplant relapse. Lowering the disease burden may
improve the effectiveness of the transplanted donor cells in
exerting the desired allogeneic graft-versus-leukemia (GVL)
effect; this effect may not sufﬁce to eradicate the disease if
the tumor burden is overwhelming. Clearly, higher pro-
portions of myeloblasts in the marrow at the time of SCT are
associated with an increased risk of post-transplant relapse
[13,16,17].
ICT appears to be more effective in patients with high
marrow blast percentages than HMAs [18,19]. Therefore, it
might be preferable in this setting to use ICT. On the other
hand, most patients with MDS are in their 60s or 70s and
therefore undergo allo-SCT after a nonmyeloablative condi-
tioning or reduced-intensity conditioning (RIC) regimen, and
most published studies show a higher relapse rate with RIC
than with higher-dose “myeloablative” conditioning, which
is typically not used in older patients [20]. Those observa-
tions were conﬁrmed in the recently closed randomized
prospective trial BMT CTN 0901, which showed superiority of
higher intensity regimens in patients AML or MDS (unpub-
lished results). Optimally reducing tumor burden before allo-
SCT is a major objective in these patients, and ICT pre-SCT
may enhance the chances of relapse-free survival after
transplantation, especially in patients with high numbers of
marrow myeloblasts without high-risk cytogenetics.
Against ICT
The median age of patients diagnosed with de novo MDS
is 70 to 75 years [21,22]. Therefore, major concerns are theside effects of intensive treatment in view of the frequently
considerable comorbidities in those patients [23]. Pretrans-
plant ICT may reduce the incidence of post-transplant
relapse but is associated with substantial morbidity and
mortality, which may prevent patients from proceeding to
allo-SCT. In fact, in a prospective study of 259 patients
50 years or older with high-risk MDS or AML, 99 patients
(37%) achieved complete remission after ICT. Of those,
however, only 53 were considered for allo-SCT and just 14
patients (5%) ultimately underwent allo-SCT. The remaining
patients were considered not suitable for allo-SCT for various
reasons, including their clinical status already before
receiving ICT [24] and effects possibly attributable to ICT.
On the other hand, ICT may not provide any beneﬁt in
patients with a low percentage of marrow blasts and, as
suggested already,may not be effective in patients with high-
risk karyotype. Indeed, in a retrospective study investigating
the impact of ICT in patients with MDS, Fenaux et al. [18]
observed signiﬁcantly lower complete remission rates in
patients with low marrow blast percentage compared with
those having more than 19% marrow myeloblasts at diag-
nosis (19% versus 69%, P ¼ .008). In that analysis, karyotype
was the only signiﬁcant prognostic factor of disease-free
interval (after therapy), with a median of 16.5 months in
patients with normal karyotype versus 4 months in patients
with abnormal cytogenetics (P ¼ .018) [18]. However, the
apparent efﬁcacy of ICT for remission induction in patients
with advanced MDS did not translate into a beneﬁt in post-
SCT outcome, neither for patients with refractory anemia
with excess blasts or with refractory anemia with excess
blasts in transformation nor in patients with transformation
to AML, regardless of the type of transplant conditioning
regimen [25].HYPOMETHYLATING AGENTS
In Favor of HMAs
HMAs are currently considered standard of care for most
patients with intermediate-2 and high-risk MDS, although
HMAs have no curative potential [9,15]. They offer several
important advantages over ICT, including the ability of
administration to outpatients, not requiring hospitalization.
In fact, patients may be able to return to their usual activities
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for nausea, which can easily be controlled by appropriate
antiemetic/antinausea medications. In addition, HMAs are
active in elderly patients and those with comorbidities and
therefore are attractive as treatment before transplant. Field
et al. [26], in a retrospective series of 30 MDS and non-MDS
patients treatedwith AZA alone or in combinationwith other
agents before allo-SCT and 24 patients who did not receive
AZA, showed comparable 1-year OS and relapse-free survival
in the 2 groups. There was a trend for a lower relapse inci-
dence in the AZA group [26].
To investigate the impact of pretransplant AZA on patient
outcome after allo-SCT for MDS, the French Society of Bone
Marrow Transplantation and the French group of myelo-
dysplasia conducted a large retrospective study that included
265 consecutive patients who underwent allo-SCT for MDS
after ICT alone (n ¼ 98), AZA alone (n¼ 48), or AZA preceded
or followed by ICT (n ¼ 17). With a median follow-up of
38.7 months, patients who received AZA alone had similar
outcomes as those who received ICT alone [27]. These data
are in line with what has been reported by the Seattle team
[28]. Therefore, with the goal of down-staging the underly-
ing disease before allo-SCT, AZA alone is a good alternative to
standard ICT.Against HMAs
Despite overall responses rate of 50% to 60%, complete
remissions are very infrequent, ranging from 7% to 17% [29].
In addition, HMAs do not seem to be effective in all patients
with MDS. Indeed, prognostic factors of response and OS
after HMAs remain largely undetermined. Itzykson et al. [19]
identiﬁed several factors that affect the depth and duration
of the response to AZA, namely, previous low-dose cytosine
arabinoside treatment, bone marrow blasts >15%, and
abnormal karyotype that independently predicted lower
response rates, whereas complex karyotypes predicted
shorter responses. On the other hand, Eastern Cooperative
Oncology Group performance status 2, International Prog-
nostic Scoring System intermediate- and poor-risk cytoge-
netics, presence of circulating blasts, and RBC transfusion
dependency (4 units/8 weeks) independently predicted
poorer OS.
Also, typically, patients need to be treated for extended
periods of time before responders/nonresponders can be
distinguished. During this extended treatment period, pa-
tients may acquire additional comorbid conditions, disease-
or treatment-related, which may increase the risk of
potentially fatal complications after SCT [30,31]. Further, a
retrospective analysis by Prebet et al. [32] indicated that
although transplantation is the most promising therapeutic
option for patients who have failed treatment with HMAs,
success of allo-SCT was not uniform. Patients who were
taken off AZA therapy because they showed disease pro-
gression had a median survival of approximately 14 months,
which was better than the 5 to 6 months in patients treated
with other modalities, but there was no evidence of a
plateau. In comparison, patients who went to allo-SCT
because they showed no response to AZA or did not
tolerate the drug had a probability of survival after trans-
plantation of about 30%. Thus, among patients on HMA
therapy, there is always a temptation to continue to treat as
long as the patient is doing well and go to allo-SCT only once
disease progression is observed. This may not be the opti-
mum strategy.NO PRETRANSPLANT TREATMENT
In Favor of Up-Front Allo-SCT
One of the limitations of all studies that have investigated
pretransplant treatment is their retrospective nature with
probable selection bias as a result of the impossibility of
accounting for patient drop-out, due to either complications
from pretransplant treatment or rapid progression of MDS to
AML. In fact, Robin et al. [31] reported an observational
prospective study of 163 patients with high-risk MDS who
were candidates for allo-SCT. Patients received either AZA
(n ¼ 117) or ICT (n ¼ 40) as pretransplant therapy. Of the 117
patients with a donor, only 69% of those with HLA-identical
donors and 57% of those with HLA-mismatched donors
were transplanted. Similar results were observed and the
same conclusions drawn from a retrospective study of 259
patients older than 50 years who received ICT before allo-SCT
for high-risk MDS or AML [24]. On the other hand, the French
Society of Bone Marrow Transplantation and Cellar Therapy
reported a retrospective study of 128 consecutive patients
with MDS who received RIC allo-SCT. Among these, 40 had
received AZA before transplant, whereas 88 were trans-
planted up-front. With a median follow-up of 60 months, 3-
year OS, relapse-free survival, cumulative incidence of
relapse, and nonrelapse mortality were similar in both
groups [33]. Based on the above, no ﬁrm recommendations
can be formulated about delaying transplantation to perform
a “debulking” treatment in patients with MDS. The decision
should be made on an individual basis, taking into account
speciﬁc patient and disease characteristics. Clearly, up-front
transplantation is an option for some patients, especially
those with live-threatening cytopenias.
Against Up-Front Allo-SCT
One could argue that no matter what treatment we give
to a patient pretransplant, in the absence of any prospective
controlled studies, there are no data to show a deﬁnite
beneﬁt for post-transplant outcome. Therefore, an approach
would be to simply proceed to transplantation, regardless of
the disease stage (and the patient’s condition). However,
there is evidence that the reduction of tumor burden may
offer a “kinetic” advantage, allowing donor cells a more
extended interval to exert a powerful GVL effect (against a
reduced disease burden in the patient). Further, treatment
with HMAs may lead to an enhanced GVL effect via up-
regulation of potential target antigens, in particular, carci-
noembryonic antigens, due to reduced DNA methylation
after treatment with HMAs [34,35]. Thus, in addition to
reducing the tumor burden (pretransplant), there may be
improved cell kill post-transplant. As stated repeatedly,
whether HMAs or ICT represent the better pretransplant
debulking strategy is not clear. Although HMAs are typically
given for several cycles, the usefulness of multiple courses of
ICT has been questioned. In any event, the timing of allo-SCT
depends not only on the state of the disease and respon-
siveness to therapy but also on the patient’s condition.
Because the eventual eradication of MDS appears to depend
on donor cell mediated GVL effects, it may not be in the pa-
tient’s best interest to delay transplantation to give another
course of ICT in a situation of apparent chemoresistance.
PROPOSAL OF AN ALGORITHM
Factors to Be Taken into Account at Transplant
Disease characteristics
As discussed, disease characteristics are very important
for the choice of pre-SCT treatment. ICT is more likely to be
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higher marrow blast counts), whereas HMAs may be more
suitable than ICT for older patients and those with
comorbidities.
Even more important than the myeloblast count are the
patient’s cytogenetics. Numerous reports indicate that the
dominant risk factor for relapse is the patient’s karyotype,
and data presented by others indicate that patients who do
have high-risk cytogenetics are less likely to respond to
treatment with ICT [18], and responses to treatment with
AZA are of short duration [6,19].
Knowledge of the molecular pathogenesis of MDS has
expanded dramatically over the past 10 years, mainly
through the identiﬁcation of major mutational targets [1,36],
and gene mutations may have an impact on response to
HMAs and survival of patients with MDS [5,36e38]. How-
ever, the results of these studies need to be validated in
prospective protocols.
Patient characteristics
Of course, in addition to disease characteristics, patient
factors must be taken into consideration. Without exception,
patients included in studies reported to date were subject to
a selection bias. The decision whether to administer pre-
transplant therapy and which modality to use is generally
based on the assessment of the patient’s condition. Patients
who present with advanced/high-risk MDS and do not have
substantial comorbid conditions are more likely to be treated
and possibly to be treated with ICT rather than HMAs.
Conversely, patients who do have comorbidities are more
likely to receive HMAs or are not treated at all; in fact, many
of those patients may not be transplanted at all. If they do
undergo SCT, this is more likely to involve an RIC regimen
with a higher risk of relapse (a reason why one might have
wanted to carry out aggressive debulking pre-SCT).
Donor availability and stem cell source
Approximately 30% of patients have HLA-matched sibling
donors, currently considered the ﬁrst choice for allo-SCT.
With more than 22 million volunteer donors now listed
worldwide, HLA-matched unrelated donors can be identiﬁed
for about 30% to 60% of patients, depending on their
ethnicity. Results with unrelated donors who are HLA-
matched by high resolution typing are comparable with
those obtained with HLA genotypically identical siblings
[39]. Although allo-SCT from HLA-mismatched donorsTable 2
Patients Who Are Candidates for Allo-SCT: Decision-Making Algorithm Based on D
Patient Characteristics Disease Characteristics
Marrow Blasts (%) Cytogen
Age >60 yr and/or comorbidities Any Any






BO indicates best option; NI, not indicated.
* As assessed by the International Prognostic Scoring System.
y Clearly, there are patients in this category who will tolerate ICT and, particula
efforts; these are very individual decisions.
z If patient can undergo allo-SCT rapidly; currently available data do not prov
cytogenetic disease.compared with HLA-matched donors led to less satisfactory
outcomes in patients with standard- or intermediate-risk
disease, the impact of HLA-mismatch appears less pro-
nounced in patient with high-risk disease [40]. Therefore, in
the absence of HLA-matched donors for a patient requiring
allo-SCT, a prolonged search in an effort to identify a fully
HLA-matched donor must be balanced against the risk of
progression of the disease while the search is ongoing.
Depending on the disease stage, prompt transplantation
with the best available donor, even if allele- or antigen-level
mismatched, may offer the best chance for survival. Cord
blood as well as HLA-haploidentical related donors could
offer alternatives for patients with advanced MDS, although
only limited data are available [41e43].
Regarding the source of stem cells, bone marrow and
peripheral blood progenitor cells show different character-
istics, in regards to the kinetics of engraftment, graft-versus-
host disease, and graft-versus-tumor effects [44]. Peripheral
blood progenitor cells provide a more potent graft-versus-
tumor effect and are therefore used preferentially in pa-
tients with advanced/high-risk disease; however, they also
carry a higher risk of chronic graft-versus-host disease
[44,45]. Despite these ﬁndings, patients conditioned with
nonmyeloablative conditioning or RIC regimens almost al-
ways receive peripheral blood progenitor cells because of
higher rates of graft failure with marrow.
Conditioning regimes
The optimumconditioning regimen for patientswithMDS
(as well as patients with other diagnoses) has yet to be
determined. The objective is, of course, to minimize toxicity
and maximize efﬁcacy. A recently completed randomized
trial under the auspices of the Blood and Marrow Transplant
Clinical Trials Network (in the United States) in patients with
MDS and AML (with less than 5%marrow blasts at the time of
SCT) has investigated whether RIC (2 regimens) or higher
intensity “myeloablative” conditioning (3 regimens) offers
superior results. Will reduced toxicity andmortality with RIC
outweigh the expected lower relapse frequency in patients
conditioned with high-intensity regimens? As indicated
above, unpublished results suggest a higher failure rate with
the use of RIC regimens. Therefore, it appears to be appro-
priate, certainly inpatients up to 60or 65 years of age, to apply
higher intensity conditioning and touseRIC regimens in older
patients and those with relevant comorbid conditions.
Ongoing trials are exploring a spectrum of regimens, andisease Characteristics and Patient Age and Comorbidities
ICT HMAs Up-Front Allo-SCT
etics*
Possibley BO Possible
risk NI BO Possible
k NI Possible BOz
risk Possible BO Possible
k NI Possible BOz
risk BO Possible Possible
k Possible Possible BOz
rly with high marrow blast counts, might beneﬁt from intensive debulking
ide strong support for chemotherapy debulking in patients with high-risk
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oped. Conversely, modiﬁcation of RIC regimens or combina-
tion with post-transplant preemptive manipulations may
maintain the low toxicity and reduce the relapse frequency.
Decision Table
The ideal strategy to discern the post-transplant beneﬁt of
pre-SCT debulking therapy and to identify the optimal
approach is a randomized prospective study. In the absence
of prospective trials, we present a “decision table” that, in the
view of the authors, may help to choose the appropriate
pretransplant strategy based on patient and disease charac-
teristics at the time when allo-SCT is considered (Table 2).
The focus of the present review is on pretransplant therapy
in patients with MDS. Clearly, however, as illustrated in
numerous publications, many factors go into the decision for
or against pretransplant therapy, for or against allo-SCT, and
into the transplant strategy to be pursued. The development
of various risk scoring schemes, such as the Hematopoietic
Cell Transplantation Comorbidity Index [46] or the Pre-
transplant Assessment of Mortality score [47], has assisted
physicians and patients in deciding about transplantation
and in selecting the optimum strategy to pursue. The
complexity of decision-making in those patients has been
discussed in a perspective article [48].
CONCLUSIONS
The answer as to the optimum strategy of MDS therapy,
particularly in regards to pretransplant therapy in patients
who are candidates for transplantation, is not clear. A pro-
spective trial has been initiated by the Seattle team (Fred
Hutchinson Cancer Research Center). This trial randomizes
patients with MDS who are transplant candidates to receive
either classical ICTor treatment with HMAs. The objectives of
the study are to determine, ﬁrst, what proportion of patients
in each arm will make it to transplantation and, second, to
assess whether one or the other pretransplant approach has
a beneﬁcial effect on post-transplant outcome.
Additional work is necessary, and if no prospective
studies are being conducted, we need to analyze very care-
fully, in retrospective data analyses, what impact, for
example, a given mutation has on post-transplant outcome
and whether such a mutation (similar to Flt3 in AML pa-
tients) could be targeted by adjuvant therapy, thereby
reducing relapse [1]. Also, as numerous immunotherapeutic
strategies are being developed, it is conceivable that the
emphasis will switch from pre-SCT to post-transplant ther-
apy, for example, in the form of genetically modiﬁed Tcells or
natural killer cells that may prevent or reduce the incidence
of post-transplant relapse.
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